Title: Innovation in Glaucoma, Cataracts, and the Future

### **Speakers:**

April L. Jasper, OD, FAAO dr@apriljasper.com

Katie Spear OD, JD, MPH Kjgilbert77@gmail.com

Carl Spear, OD, FAAO, MBA CHspear@gmail.com

Nate Lighthizer, OD, FAAO Lighthiz@nsuok.edu

**CE Hours:** (2) Live Lecture

**Description:** In this course, the panelists will look at current research results and innovations in glaucoma, cornea and retinal disease diagnosis and treatment and will discuss what the future looks like in these areas. Review of some of the current accepted treatments in each area will be discussed and how we can move forward in adopting the new. Attendees will leave with a better understanding of the current landscape of each, what to watch for and what to do today in practice.

## **Objectives:**

To understand clinical trials that apply to glaucoma diagnosis and treatment today and in the future.

To understand clinical trials that apply to corneal disease diagnosis and treatment today and in the future.

To understand clinical trials that apply to retinal disease diagnosis and treatment today and in the future.

To understand how we can apply the research and innovation in glaucoma in practice today.

To understand how we can apply the research and innovation in cornea in practice today.

To understand how we can apply the research and innovation in retina in practice today.

### **Outline:**

- A. What is the danger of not knowing what new innovation is available for our patient's diagnosis and treatment? (10 min) April
  - 1. Poor Outcomes
  - 2. Decreased patient compliance.
  - 3. Reduced ability for further research to take place.
  - 4. Reduced practice growth
  - 5. Other
- B. <u>Clinical trials that apply to glaucoma diagnosis and treatment we should be aware of today? https://eyewiki.aao.org/Clinical Trials in Glaucoma</u>
- 1. OHTS: Ocular Hypertension Treatment Study
  - a. Objectives, design, main outcome measure
  - b. Results, limitations, conclusions
- 2. EMGT: Early manifest Glaucoma Trial
  - a. Objectives, design, main outcome measure
  - b. Results, limitations, conclusions
- 3. CNTGS: Collaborative Normal tension glaucoma study
  - a. Objectives, design, main outcome measure
  - b. Results, limitations, conclusions
- 4. LoGTS
  - a. Objectives, design, main outcome measure
  - b. Results, limitations, conclusions
- 5. AVB

- a. Objectives, design, main outcome measure
- b. Results, limitations, conclusions

### 6. LiGHT

- a. Objectives, design, main outcome measure
- b. Results, limitations, conclusions

### 7. GLT

- a. Objectives, design, main outcome measure
- b. Results, limitations, conclusions

#### 8. Other

- a. Objectives, design, main outcome measure
- b. Results, limitations, conclusions
- C. <u>Clinical trials that apply to corneal disease diagnosis and treatment we should be aware of today? https://eyewiki.org/Clinical Trials in Cornea</u>

# 1. HEDS-1

- a. Objectives, design, main outcome measure
- b. Results, limitations, conclusions
- 2. Keratoconus and treatment options available
  - a. Objectives, design, main outcome measure
  - b. Results, limitations, conclusions
- 3. Neurotrophic Keratitis
  - c. Objectives, design, main outcome measure
  - d. Results, limitations, conclusions

### 4. Other

- e. Objectives, design, main outcome measure
- f. Results, limitations, conclusions
- D. <u>Clinical trials that apply to retinal disease diagnosis and treatment we should be aware of today?</u>

- 1. CATT (Comparison of Age-related Macular Degeneration Treatment Trials)
  - a. Objectives, design, main outcome measure
  - b. Results, limitations, conclusions
- 2. EVEREST and PLANET study
  - a. Objectives, design, main outcome measure
  - b. Results, limitations, conclusions
- 3. ETDRS (Early Treatment Diabetic Retinopathy Study)
  - a. Objectives, design, main outcome measure
  - b. Results, limitations, conclusions
- 4. DRCR.net (Diabetic Retinopathy Clinical Research network)
  - a. Protocol S PRP vs IVR with deferred PRP for PDR study
    - 1. Objectives, design, main outcome measure
    - 2. Results, limitations, conclusions
  - b. Protocol T: A comparative Effectiveness Study of Intravitreal Afibercept,
    Bevacizumab and Ranibizumab for Diabetic Macular Edema
- 5. BVOS (Branch Vein Occlusion Study)
  - a. A mulitOcenter, prospective, randomized, controlled clinical trial on 500 patients
  - b. Objectives, design, main outcome measure
  - c. Results, limitations, conclusions

\_

- 6. BRAVO (Ranibizumab for macular edema due to BRVO)
  - a. Objectives, design, main outcome measure
  - b. Results, limitations, conclusions
- 7. CVOS (Central Vein Occlusion Study):
  - a. A multi-center, prospective, randomized, controlled clinical trial including 728 eyes of 725 patients seen in nine clinics with signs of CRVO
  - a. Objectives, design, main outcome measure
  - b. Results, limitations, conclusions
- E. How can we apply the research and innovation in glaucoma in practice today?
  - 1. In providing better patient care
  - 2. In achieving better outcomes
  - 3. In determining needed technology for the practice or team trainings
- F. How can we apply the research and innovation in cornea in practice today?
  - 1. In providing better patient care
  - 2. In achieving better outcomes

- 3. In determining needed technology for the practice or team trainings
- G. How can we apply the research and innovation in retina in practice today?
  - 1. In providing better patient care
  - 2. In achieving better outcomes
  - 3. In determining needed technology for the practice or team trainings
- H. How should we all stay up to date with the latest research?
- I. How should we all stay up to date with how to best implement the latest research?